Search company, investor...

Predict your next investment

Tao Capital company logo
Venture Capital
taocapital.cn

Investments

42

Portfolio Exits

4

About Tao Capital

Tao Capital a venture capital firm that invests in companies in pharmaceuticals, medical devices, biotechnology, medical services, and digital healthcare in different stages from seed to pre-IPO.

Headquarters Location

2602-03, Tower B, Global Trade Center No. 36 North Third Ring East Road, Dongcheng District

Beijing, Beijing,

China

86-010-5629-3025

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest Tao Capital News

SiYi Intelligence Raises Nearly $15 Million in Series A Financing

Mar 6, 2023

Share SiYi Intelligence , an intelligent rehabilitation solution provider, completed nearly 15 million US dollars in Series A financing. This round was led by Chengdu Bio-town Equity Investment Fund with participation from existing investor Tao Capital. The company plans to use the funding to accelerate the R&D of integration solutions for neurorehabilitation and build the digital rehabilitation service platform. SiYi intelligence leadership team is composed of doctors and masters from Top universities such as Shanghai Jiao Tong University, Harbin Institute of Technology, and Jilin University; most of them have over 10 years of experience in the robotics, healthcare and rehabilitation industry. With industrial system thinking and multidisciplinary know-how, SiYi has innovated a series of professional rehabilitation robots for scientific research and clinical and family use. They have released worldwide hit product- SYREBO soft robotic hand rehabilitation glove, EasyWalk exoskeleton walking suit for lower extremity augmentation, EEG-based assistive BCIs, and SYREBO upper limb rehabilitation robot A2 for both clinical and home use. To accelerate the implementation and verification of clinical rehabilitation theory, SiYi has carried out in-depth cooperation with Shanghai Jiao Tong University, Tohoku University in Japan, The Royal Buckinghamshire Hospital (RBH) in the UK, Manus Brescia Rehabilitation Center in Italy, Hongkong ShaTin Hospital and other international academic and medical institutions. By 2022, the company has over 30 authorized patents, over 50 registered trademarks, and more than 10 software copyrights. It has also been awarded as “National High-tech Enterprise”, “Shanghai Patent Work Pilot Unit” and “Shanghai Pudong New Area Recognized Research and Development Institution”. “As an innovative enterprise focusing on rehabilitation robotics, we are aware of the existing social problems in the rehabilitation industry, such as the shortage of medical resources, the serious shortage of community and family rehabilitation resources, and the acceleration of population aging. Therefore, we uphold the vision of ‘enabling everyone to enjoy innovative rehabilitation services’, to innovate professional rehabilitation robots that is affordable and effective for everyone. Fortunately, our products have entered over 3,000 medical units, serving millions of patients all over the world. It is also fortunate that we have met investors with similar ambitions, which help us accelerate the innovation and development of integrated solutions for neurological rehabilitation and build a digital rehabilitation service platform, so as to jointly boost the rehabilitation industry towards a more brilliant future.” said Gavin Yin, founder & CEO of SiYi Intelligence. Related Posts “SiYi intelligence has a comprehensive team with rich experience in rehabilitation and robotic technology; they have a deep understanding of the industry and a wealth of patent achievement in the technical field. Their products have also reached a wide market. We look forward to SiYi launching more innovative rehabilitation products to provide more choices and better services for patients,” said the investment team of Chengdu Bio-town Equity Investment Fund. “With the hand rehabilitation service as the entry point, SiYi intelligence constantly extends its product line and services. Their integration rehabilitation platform covering the whole cycle of clinical, community and family has remarkable characteristics and industry differentiation,” said Dafeng Zhang, the Chairman of Tao Capital. ” We firmly believe in SiYi and keep investing in them. The rehabilitation system in China is undergoing a transformation, and SiYi has formed a new force in the industry by innovating technology and business models. In the future, we look forward to exploring a better future for the rehabilitation industry and creating stronger social value together with SiYi Intelligence.”

Tao Capital Investments

42 Investments

Tao Capital has made 42 investments. Their latest investment was in Huichuang Medical as part of their Series B on October 10, 2023.

CBI Logo

Tao Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/31/2023

Series B

Huichuang Medical

$13.66M

No

2

9/11/2023

Series B - II

Oriomics

$13.62M

Yes

2

6/26/2023

Seed VC

KangaBio

$13.82M

Yes

2

3/6/2023

Series A

Subscribe to see more

$99M

Subscribe to see more

10

12/20/2022

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/31/2023

9/11/2023

6/26/2023

3/6/2023

12/20/2022

Round

Series B

Series B - II

Seed VC

Series A

Series C

Company

Huichuang Medical

Oriomics

KangaBio

Subscribe to see more

Subscribe to see more

Amount

$13.66M

$13.62M

$13.82M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

2

10

10

Tao Capital Portfolio Exits

4 Portfolio Exits

Tao Capital has 4 portfolio exits. Their latest portfolio exit was AGS MedTech on May 19, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/19/2023

IPO

$99M

Public

1

7/28/2022

IPO

Subscribe to see more

$99M

Subscribe to see more

10

7/5/2022

IPO

Subscribe to see more

$99M

Subscribe to see more

10

1/18/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/19/2023

7/28/2022

7/5/2022

1/18/2021

Exit

IPO

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

Tao Capital Team

1 Team Member

Tao Capital has 1 team member, including current Founding Partner, Dafeng Zhang.

Name

Work History

Title

Status

Dafeng Zhang

Founding Partner

Current

Name

Dafeng Zhang

Work History

Title

Founding Partner

Status

Current

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.